| http://www.w3.org/ns/prov#value | - Michael Severino, Amgen's vice president of research and development, said in an interview on Monday that the company believes Xgeva does provide a clinically meaningful benefit because it delays the spread of cancer to the bone, which causes significant pain and other problems such as incontinence.
|
